Posted by Michael Wonder on 21 Jul 2021
Venetoclax (Venclexta) granted US FDA breakthrough therapy designation in higher risk myelodysplastic syndrome
21 July 2021 - This is the sixth breakthrough therapy designation granted for venetoclax as AbbVie continues to show ongoing commitment across blood cancers including tough to treat myeloid malignancies.
AbbVie announced today that the U.S. FDA granted a breakthrough therapy designation to venetoclax (Venclexta) in combination with azacitidine for the potential treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes based on revised International Prognostic Scoring System.
